Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Alvotech

Market Cap 1.22B 1.05B 969M 912M 1.71B 115B 1.73B 11.49B 4.47B 56.6B 4.59B 4.49B 196B P/E 2026 *
9.78x
P/E 2027 * 8.96x
Enterprise Value 2.32B 2B 1.84B 1.73B 3.26B 219B 3.28B 21.82B 8.49B 108B 8.71B 8.53B 372B EV / Sales 2026 *
3.51x
EV / Sales 2027 * 2.99x
Free-Float
36.85%
Yield 2026 *
-
Yield 2027 * -
1 day+1.16%
Current month-58.26%
Current year-58.26%
5 years 3.75
Extreme 3.75
10.44
10 years 3.75
Extreme 3.75
11.62
Manager TitleAgeSince
Chief Executive Officer 55 01/03/2026
Director of Finance/CFO 48 10/07/2025
Chief Tech/Sci/R&D Officer - 01/01/2023
Director TitleAgeSince
Chairman 56 01/01/2019
Director/Board Member 64 01/01/2019
Director/Board Member 58 01/01/2019
Date Insider Type Main position Quantity % Market Cap.
21/09/20OthersCompany 218,750 3.8889%
16/09/20OtherCompany 0 0%
16/09/20OtherCompany 6,468,750 115.0000%
Change 5-day change 1-year change 3-year change Capi.($)
+1.16%-5.43% - - 1.22B
-0.22%-1.14%-11.88%-13.09% 43.44B
+0.76%+9.42%+303.09%+540.82% 33.54B
-4.74%-6.31%+10.75%-20.99% 28.48B
-0.47%-0.35%+3.38%+31.20% 29.2B
+0.06%+4.36%+13.31%+21.11% 25.34B
-0.02%+10.18% - - 14.36B
-0.98%-1.86%+53.43%+106.06% 13.05B
-0.29%-4.40%+3.13%+1.69% 12.67B
+1.67%+1.35%+105.56%+81.16% 12.28B
Average -0.31%+1.33%+60.10%+93.50% 23.6B
Weighted average by Cap. -0.59%+1.35%+62.75%+105.16%

Financials

2026 *2027 *
Net sales 661M 570M 524M 493M 927M 62.36B 935M 6.21B 2.42B 30.6B 2.48B 2.43B 106B 784M 676M 622M 585M 1.1B 73.98B 1.11B 7.37B 2.87B 36.31B 2.94B 2.88B 126B
Net income 165M 142M 131M 123M 231M 15.57B 233M 1.55B 604M 7.64B 619M 606M 26.43B 134M 116M 106M 100M 188M 12.65B 190M 1.26B 491M 6.21B 503M 492M 21.48B
Net Debt 1.1B 948M 872M 820M 1.54B 104B 1.55B 10.33B 4.02B 50.9B 4.12B 4.04B 176B 1.12B 966M 888M 836M 1.57B 106B 1.58B 10.52B 4.1B 51.85B 4.2B 4.11B 179B
Logo Alvotech
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Employees
1,279
Date Price Change Volume
17/06/26 3.915 $ +1.16% 882,239
16/06/26 3.870 $ -8.73% 5,493,541
15/06/26 4.240 $ +1.68% 641,310
12/06/26 4.170 $ -1.18% 533,766
11/06/26 4.220 $ +1.93% 896,656
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
3.915USD
Average target price
13.83USD
Spread / Average Target
+253.34%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!